Back to top
more

Roche Holding (RHHBY)

(Delayed Data from OTC)

$39.26 USD

39.26
1,211,621

+0.45 (1.16%)

Updated Nov 1, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (60 out of 250)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Blueprint (BPMC) Q4 Earnings Beat, Stock Up as Ayvakit Shines

by Zacks Equity Research

Blueprint (BPMC) climbs 14% on better-than-expected fourth-quarter 2023 results, driven by increased Ayvakit sales following the drug's label expansion for the ISM indication.

Biogen (BIIB) Q4 Earnings & Sales Miss Estimates, Stock Falls

by Zacks Equity Research

Biogen (BIIB) misses fourth-quarter estimates for earnings and sales. Sales of Tecfidera, Tysabri & Spinraza decline.

Regeneron (REGN) Q4 Earnings & Sales Top, Eylea Sales Decline

by Zacks Equity Research

Regeneron (REGN) beats earnings and sales estimates in fourth-quarter 2023, fueled by Dupixent. However, sales of the lead drug, Eylea, continue to fall.

Roche (RHHBY) 2023 Earnings Miss, COVID-19 Product Sales Down

by Zacks Equity Research

Roche (RHHBY) misses earnings and sales estimates in 2023 due to a significant decline in COVID-19-test sales. Currency rate fluctuations also impact results.

Novartis (NVS) Q4 Earnings Miss on Higher Costs, Sales Lag

by Zacks Equity Research

Novartis' (NVS) earnings and sales miss estimates in the fourth quarter. The outlook for 2024 does not look promising as well.

Solid Biosciences' (SLDB) DMD Drug Gets Orphan Tag, Stock Up

by Zacks Equity Research

Solid Biosciences (SLDB) stock rises after the FDA grants the orphan drug designation to the company's novel gene-therapy candidate, SGT-003, for the treatment of Duchenne muscular dystrophy.

Regeneron (REGN), Sanofi's Dupixent Gets Label Update in US

by Zacks Equity Research

The FDA updates Regeneron (REGN) and Sanofi's Dupixent label in the United States to include efficacy and safety data for patients aged 12 years and older with atopic dermatitis with uncontrolled moderate-to-severe hand and/or foot involvement.

Roche's (RHHBY) Tecentriq Subcutaneous Gets Approval in the EU

by Zacks Equity Research

Roche's (RHHBY) subcutaneous formulation of immuno-oncology drug Tecentriq receives EC's approval for all approved indications.

The Zacks Analyst Blog Highlights Roche, Netflix, NIKE, Uber, Technologies and Prologis

by Zacks Equity Research

Roche, Netflix, NIKE, Uber, Technologies and Prologis are part of the Zacks top Analyst Blog.

Mark Vickery headshot

Top Research Reports for Roche, Netflix & NIKE

by Mark Vickery

Today's Research Daily features new research reports on 16 major stocks, including Roche Holding AG (RHHBY), Netflix, Inc. (NFLX) and NIKE, Inc. (NKE).

Why Sarepta's (SRPT) Stock Price Moved Up 17% on Tuesday

by Zacks Equity Research

Sarepta (SRPT) surges after its CEO made positive comments on the label expansion filing for the company's DMD gene therapy. The company expects a potential approval in August.

Prothena's (PRTA) Update on Pipeline Progress Disappoints

by Zacks Equity Research

Prothena (PRTA) provides updates on PRX012, PRX123, birtamimab and other programs. The delay in phase III data on birtamimab disappoints investors.

Regeneron (REGN) Down as Q4 Eylea Preliminary Sales Disappoint

by Zacks Equity Research

Regeneron (REGN) shares decline after it announces preliminary Q4 sales for the ophthalmology drug Eylea.

Sarepta (SRPT) Rises on Solid Q4 and 2023 Preliminary Results

by Zacks Equity Research

Sarepta (SRPT) issues encouraging preliminary results for the fourth quarter and full-year 2023. Shares of the company rise.

Omega (OMGA) Up 95% on Obesity Drug Deal With Novo Nordisk

by Zacks Equity Research

Using Omega's (OMGA) proprietary technology platform, Novo Nordisk (NVO) intends to develop a novel therapeutic for obesity, which will enhance the body's metabolism activity to burn excess fats.

Roche (RHHBY) to Acquire LumiraDx's Point of Care Technology

by Zacks Equity Research

Roche (RHHBY) is set to acquire LumiraDx's Point of Care technology for $295 million and an additional payment of up to $55 million.

Sarepta (SRPT) Seeks Label Expansion for DMD Gene Therapy

by Zacks Equity Research

Sarepta (SRPT) files a supplement with the FDA seeking to expand its recently-approved gene therapy Elevidys' label to treat all DMD patients, regardless of age and ambulatory status.

Roche's (RHHBY) sBLA for Xolair Gets FDA Priority Review Tag

by Zacks Equity Research

The FDA accepts and grants priority review to Roche's (RHHBY) supplemental biologics license application for Xolair for the reduction of food allergic reactions. A decision is due in the first quarter of 2024.

LLY Down as Patients Regain Weight After Stopping Zepbound

by Zacks Equity Research

Full results from a late-stage study show that patients who stopped taking Eli Lilly's (LLY) weight-loss drug for over a year slowly started to regain their lost weight.

Regeneron (REGN) Posts Positive Data on Blood Cancer Candidate

by Zacks Equity Research

Regeneron's (REGN) multiple myeloma candidate demonstrates strong rates and depth of response in pre-treated patients.

Solid Biosciences' (SLDB) DMD Drug Gets Fast Track Tag, Stock Up

by Zacks Equity Research

Solid Biosciences (SLDB) gains 68% as the FDA grants Fast Track designation to the company's gene therapy candidate, SGT-003, for the treatment of Duchenne muscular dystrophy.

The Zacks Analyst Blog Highlights Alphabet, NVIDIA, Roche, Intuit and AT&T

by Zacks Equity Research

Alphabet, NVIDIA, Roche, Intuit and AT&T are included in this Analyst Blog.

Sheraz Mian headshot

Top Research Reports for Alphabet, NVIDIA & Roche

by Sheraz Mian

Today's Research Daily features new research reports on 16 major stocks, including Alphabet Inc. (GOOGL), NVIDIA Corporation (NVDA) and Roche Holding AG (RHHBY).

Roche (RHHBY) Breast Cancer Drug Meets Primary Goal in Phase III

by Zacks Equity Research

Roche's (RHHBY) phase III study evaluating inavolisib in combination with advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation achieves its primary goal.

Mark Vickery headshot

Small-Cap Russell Leads the Way, Jobs Data to Come

by Mark Vickery

Only the small-cap Russell 2000 managed to stay above zero the entire trading day.